The FDA has resumed posting complete response letters (CRLs) after a pause in new CRL releases earlier in the week, pointing to its “commitment to transparency.” The restart comes as multiple biopharma programs continue to face regulatory timing risk and manufacturing scrutiny. In parallel, the FDA posted 14 new rejection letters online, signaling that review bottlenecks are back in motion for companies seeking approvals. For sponsors, the change increases urgency around understanding whether CRL drivers are remediable manufacturing issues, data adequacy gaps, or labeling/CMC deficiencies. The agency’s messaging suggests a renewed emphasis on publicly communicating rejection outcomes while the industry continues to adjust to evolving FDA review processes and documentation expectations.